Evidence map›Paper›PMID 36017075›Full record

ArticleFrontiers in molecular neuroscience2022

Activation of the GABA-alpha receptor by berberine rescues retinal ganglion cells to attenuate experimental diabetic retinopathy.

Wangyi Fang, Xiaojing Huang, Kaicheng Wu, Yuan Zong, Jian Yu, Huan Xu, Jiemei Shi, Jiaojiao Wei, Xujiao Zhou, Chunhui Jiang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. The potential role of amino acids in myopia: inspiration from metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2024
    Review
  9. Dopamine: A New Player in the Pathogenesis of Diabetic Retinopathy?International journal of molecular sciences · 2024
    Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Wangyi FangDepartment of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China.
Xiaojing HuangDepartment of Ophthalmology, Shanghai Pudong New Area Gongli Hospital, Shanghai, China.
Kaicheng WuDepartment of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China.
Yuan ZongDepartment of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China.
Jian YuDepartment of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China.
Huan XuDepartment of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China.
Jiemei ShiDepartment of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China.
Jiaojiao WeiDepartment of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China.
Xujiao ZhouDepartment of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China.
Chunhui JiangDepartment of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China.
Eye & ENT Hospital of Fudan University · CNSecond Military Medical University · CNShanghai Children's Hospital · CNState Key Laboratory of Medical Neurobiology

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The aim of this study was to investigate the role and mechanism of berberine (BBR) in the protection of injured retinal ganglion cells (RGCs) in diabetic retinopathy (DR). Methods: Experimental diabetic retinopathy rat model was successfully induced by a single intraperitoneal injection of streptozotocin (STZ, 60 mg/kg) in male SD rats with sufficient food and water for 8 weeks. Animals were randomly divided into four groups: (1) non-diabetic, (2) diabetic, (3) diabetic + BBR + PBS, and (4) diabetic + BBR + SR95531. BBR (100 mg/kg) was given daily by gavage to rats in the group (3) and group (4) for 8 weeks, and weekly intravitreal injections were conducted to rats in the group (3) with 5 μL of 1×PBS and rats in the group (4) with 5 μL of GABA-alpha receptor antagonist SR95531 to investigate the underlying mechanisms. The survival and apoptosis of RGCs were observed by fluorescence gold labeling technology and TUNEL staining. Visual function was evaluated by visual electrophysiological examination. Western blotting and immunofluorescence staining were used to analyze the expression of GABA-alpha receptors in RGCs. Results: In an animal model, BBR can increase the survival of RGCs, reduce RGCs apoptosis, and significantly improve the visual function. The reduction of GABA, PKC-α, and Bcl-2 protein expression caused by DR can be considerably increased by BBR. SR95531 inhibits BBR's protective effect on RGC and visual function, as well as its upregulation of PKC-α and Bcl-2. Conclusion: BBR is a promising preventive or adjuvant treatment for DR complications, and its key protective effect may involve the regulation of RGC apoptosis through the GABA-alpha receptor/protein kinase C-alpha (GABAAR/PKC-α) pathway.

Indexed as

berberinediabetic retinopathyGABA receptorneuroprotectionretinal ganglion cell

Identifiers

PMID36017075
PMCPMC9396352
OpenAlexW4292454398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.